ICS (biocon Pharma Inc) Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: ICS (biocon Pharma Inc) Pharmaceutical Import Records from India — 2 Products, $19.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

ICS (biocon Pharma Inc) — Pharmaceutical Importer Profile (2026) | 2 Products, $19.6M Trade | TransData Nexus

ICS (biocon Pharma Inc)

Pharmaceutical Importer · United States · Cardiovascular Focus · $19.6M Total Trade · DGFT Verified

ICS (biocon Pharma Inc) is a pharmaceutical importer based in United States with a total trade value of $19.6M across 2 products in 2 therapeutic categories. Based on 392 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. ICS (biocon Pharma Inc) sources from 1 verified Indian supplier, with Graviti Pharmaceuticals Private Limited accounting for 100.0% of imports.

ICS (biocon Pharma Inc) — Import Portfolio & Supplier Network

ICS (biocon Pharma Inc) import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to ICS (biocon Pharma Inc)?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Graviti Pharmaceuticals Private Limited	$1.1M	29	100.0%

ICS (biocon Pharma Inc) sources from 1 verified Indian supplier across 29 distinct formulations. The sourcing is highly concentrated — Graviti Pharmaceuticals Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Atorvastatin calcium tablets USP 20MG 11816x1000 s	$50.0K	1
Atorvastatin calcium tablets USP 40MG 44032x90 s	$50.0K	1
Atorvastatin calcium tablets USP 40MG 5950x1000 s	$50.0K	1
Atorvastatin calcium tablets USP 10MG 7792x1000 s	$50.0K	1
Atorvastatin calcium tablets USP 20MG 5296x1000 s	$50.0K	1
Atorvastatin calcium tablets USP 20MG 10464x1000 s	$50.0K	1
Atorvastatin calcium tablets USP 40MG 5983x1000 s	$50.0K	1
Atorvastatin calcium tablets USP 80MG 5928x1000 s	$50.0K	1
Atorvastatin calcium tablets USP 40MG 15877x1000 s	$50.0K	1
Atorvastatin calcium tablets USP 40MG 3952x1000 s	$50.0K	1
Atorvastatin calcium tablets USP 10MG 15685x1000 s	$50.0K	1
Atorvastatin calcium tablets USP 40MG 3936x1000 s	$50.0K	1
Atorvastatin calcium tablets USP 80MG 1968x1000 s	$50.0K	1
Atorvastatin calcium tablets USP 20MG 21125x1000's	$50.0K	1
Atorvastatin calcium tablets USP 20MG 3880x1000 s	$42.4K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Atorvastatin	Cardiovascular	$9.8M	196	0.9%	11
2	Calcium	Vitamins & Supplements	$9.8M	196	1.1%	9

ICS (biocon Pharma Inc) imports 2 pharmaceutical products across 2 categories into United States totaling $19.6M.

ICS (biocon Pharma Inc) — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

ICS (Biocon Pharma Inc.) is a pharmaceutical importer and buyer based in the United States, specializing in the acquisition of finished pharmaceutical formulations from India. The company operates as a subsidiary of Biocon Limited, a leading biopharmaceutical firm headquartered in Bangalore, India. Biocon Limited is renowned for its focus on delivering affordable and high-quality medicines globally, with a diverse portfolio encompassing generics, biosimilars, and novel biologics.

Biocon Pharma Inc. plays a pivotal role in the U.S. pharmaceutical distribution network by importing and distributing a range of pharmaceutical products sourced from its parent company's manufacturing facilities in India. This strategic positioning enables Biocon Pharma Inc. to leverage Biocon Limited's extensive research and development capabilities, ensuring a consistent supply of innovative and cost-effective therapies to the U.S. market. The company's operations are primarily centered in Iselin, New Jersey, serving as a key hub for its U.S. distribution activities.

2Distribution Network

Biocon Pharma Inc. maintains a robust distribution network within the United States, with its primary operational base located at 485 US Highway 1 S, Iselin, New Jersey. This strategic location facilitates efficient logistics and distribution across the U.S. market. Additionally, the company operates a warehouse at 6450 La Salle Drive, Suite D, Lockbourne, Ohio, which serves as a critical point for receiving and processing shipments.

The company's logistics capabilities are designed to ensure timely and reliable delivery of pharmaceutical products. By leveraging its parent company's manufacturing facilities in India, Biocon Pharma Inc. can source a diverse range of products, including atorvastatin and calcium tablets, which are then distributed throughout the United States. This distribution network underscores the company's commitment to providing high-quality, affordable medications to patients across the U.S.

3Industry Role

Biocon Pharma Inc. functions as a pharmaceutical importer and distributor within the United States, focusing on sourcing finished pharmaceutical formulations from its parent company, Biocon Limited, in India. The company's role is integral to the U.S. pharmaceutical supply chain, as it bridges the manufacturing capabilities of Biocon Limited with the distribution needs of the U.S. market. By importing and distributing these products, Biocon Pharma Inc. ensures the availability of cost-effective and high-quality medications to U.S. healthcare providers and patients.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — ICS (biocon Pharma Inc)

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Biocon Pharma Inc. exhibits a high degree of sourcing concentration, importing finished pharmaceutical formulations exclusively from a single supplier, Biocon Limited. This single-source dependency reflects a strategic choice to maintain control over product quality, supply chain consistency, and cost management. The company's import data indicates a consistent volume of shipments, suggesting a stable and reliable relationship with its supplier. For instance, in August 2023, Biocon Pharma Inc. received multiple shipments of atorvastatin calcium tablets from Biocon Limited, underscoring the ongoing and dependable nature of this partnership.

While this sourcing strategy offers advantages in terms of quality control and supply chain efficiency, it also presents potential risks associated with over-reliance on a single supplier. To mitigate these risks, Biocon Pharma Inc. may consider diversifying its supplier base or establishing contingency plans to ensure uninterrupted product availability in the event of supply chain disruptions.

2Supply Chain Resilience

Biocon Pharma Inc.'s supply chain resilience is closely tied to its relationship with Biocon Limited, its sole supplier. The company's import data reveals a consistent pattern of shipments, indicating a stable and reliable supply chain. For example, in August 2023, Biocon Pharma Inc. received multiple shipments of atorvastatin calcium tablets from Biocon Limited, highlighting the ongoing and dependable nature of this partnership.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA ensures that imported drugs meet the required safety, efficacy, and quality standards before they can be marketed in the U.S.

Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which provides the legal framework for the FDA's regulatory activities. Additionally, the Drug Enforcement Administration (DEA) regulates controlled substances, ensuring that imports comply with the Controlled Substances Act.

For Indian generics to be marketed in the U.S., they must undergo the FDA's New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) process, demonstrating bioequivalence to the reference listed drug. This process involves rigorous evaluation of clinical and manufacturing data to ensure the generic's safety and efficacy.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the U.S. are stringent, with all imported drugs subject to FDA approval. Manufacturers and distributors must register with the FDA and comply with Good Manufacturing Practice (GMP) regulations to ensure product quality and safety.

The FDA recognizes GMP certifications from other regulatory bodies, such as the European Medicines Agency (EMA) and the World Health Organization (WHO), provided they meet FDA standards. This recognition facilitates the importation of pharmaceutical products from countries with established regulatory frameworks.

ICS (biocon Pharma Inc) — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Biocon Pharma Inc.'s product strategy focuses on importing finished pharmaceutical formulations in the cardiovascular and vitamins & supplements therapeutic categories. The company's import data indicates a balanced distribution between these categories, each accounting for 50% of the total import value. This strategic focus aligns with the growing demand for treatments addressing cardiovascular diseases and nutritional supplements in the U.S. market.

The market demand for these products is driven by the prevalence of cardiovascular conditions and the increasing awareness of the importance of nutritional supplements for overall health. By concentrating on these therapeutic areas, Biocon Pharma Inc. aims to meet the specific needs of U.S. patients and healthcare providers, offering effective and affordable treatment options.

2Sourcing Profile

Biocon Pharma Inc. employs a sourcing strategy centered on importing generic drug formulations from its parent company, Biocon Limited, in India. The company's import data reveals a focus on formulations such as atorvastatin and calcium tablets, indicating a preference for widely used and cost-effective medications. This approach allows Biocon Pharma Inc. to leverage Biocon Limited's manufacturing capabilities and established regulatory compliance to ensure a consistent supply of high-quality products.

India's role in Biocon Pharma Inc.'s overall procurement strategy is significant, serving as the primary source of pharmaceutical products. The country's robust pharmaceutical manufacturing sector, adherence to international quality standards, and competitive pricing make it an ideal partner for Biocon Pharma Inc.'s sourcing needs.

Frequently Asked Questions — ICS (biocon Pharma Inc)

What products does ICS (biocon Pharma Inc) import from India?

ICS (biocon Pharma Inc) imports 2 pharmaceutical products across 2 categories. Top imports: Atorvastatin ($9.8M), Calcium ($9.8M).

Who supplies pharmaceuticals to ICS (biocon Pharma Inc) from India?

ICS (biocon Pharma Inc) sources from 1 verified Indian suppliers. The primary supplier is Graviti Pharmaceuticals Private Limited (100.0% of imports, $1.1M).

What is ICS (biocon Pharma Inc)'s total pharmaceutical import value?

ICS (biocon Pharma Inc)'s total pharmaceutical import value from India is $19.6M, based on 392 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does ICS (biocon Pharma Inc) focus on?

ICS (biocon Pharma Inc) imports across 2 categories. The largest: Cardiovascular (50.0%), Vitamins & Supplements (50.0%).

Get Full ICS (biocon Pharma Inc) Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.

ICS (biocon Pharma Inc)

ICS (biocon Pharma Inc) — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to ICS (biocon Pharma Inc)?

What Formulations Does ICS (biocon Pharma Inc) Import?

What Products Does ICS (biocon Pharma Inc) Import?

Top Products by Import Value

ICS (biocon Pharma Inc) Therapeutic Categories — 2 Specializations